Showing 4771-4780 of 8827 results for "".
- FDA Approves Expanded Use of the RECELL System for Extensive Burns and Pediatric Patientshttps://practicaldermatology.com/news/fda-approves-expanded-use-of-the-recell-system-for-extensive-burns-and-pediatric-patients/2460831/The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. Specifically, RECELL is now in
- Merz Aesthetics Launches New Online Aesthetics Education Platformhttps://practicaldermatology.com/news/merz-aesthetics-launches-new-online-aesthetics-education-platform/2460830/Merz Aesthetics is launching Merz Aesthetics Medical Forum, an online medical aesthetics education platform for health care professionals around the world. Established by Merz Aesthetics Global Medical Affairs, the Medical Forum provides on-demand content focused on medical aesthe
- FDA Grants Breakthrough Device Status to Alpha DaRT for SCChttps://practicaldermatology.com/news/fda-grants-breakthrough-device-status-to-alpha-dart-for-scc/2460829/The U.S. Food and Drug Administration (FDA) granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma (SCC) of the skin and oral cavity without curative standard of care. Alpha Tau submitted data to the FDA supporting this de
- Allergan Aesthetics, Botox Cosmetic Unveil "See Yourself" Campaign with Real Stories from Real Patientshttps://practicaldermatology.com/news/allergan-aesthetics-botox-cosmetic-unveil-see-yourself-campaign-with-real-stories-from-real-patients/2460828/Allergan Aesthetics is launching "See Yourself," a new campaign featuring documentary-style shorts that tell the stories of real Botox Cosmetic patients. Watch 'See Yourself' shorts at www.BotoxCosmetic.com and @Bot
- EULAR: Data Show Benefit of Tremfya in PsA After Anti-TNF Failurehttps://practicaldermatology.com/news/eular-day-shown-benefit-of-tremfya-in-psa-after-anti-tnf-failure/2460834/New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Trem
- SkinSAFE, CVS Name Top 25 2021 Sunscreen Award Winners for Sensitive Skinhttps://practicaldermatology.com/news/skinsafe-cvs-name-top-25-2021-sunscreen-award-winners-for-sensitive-skin/2460826/SkinSAFE partnered with CVS Pharmacy, through the retailer's "Sensitive-Friendly" program, for the first-ever awards that recognize popular products that are safe for sensitive skin types. The experts at
- Can Blocking the Function of the CCR6 Chemokine Help Treat Psoriasis and Psoriatic Arthritis?https://practicaldermatology.com/news/can-blocking-the-function-of-the-ccr6-chemokine-help-treat-psoriasis-and-psoriatic-arthritis/2460825/A novel chemical blocker targeting chemokine proteins may significantly reduce skin and joint inflammation in psoriasis and psoriatic arthritis, according to a study in mice. Chemokines are small molecules with a critical role in the body’s response to inflammation and infection.
- Sofwave Medical Goes Public on the Tel Aviv Stock Exchangehttps://practicaldermatology.com/news/sofwave-medical-goes-public-on-the-tel-aviv-stock-exchange/2460824/Sofwave Medical made its initial public offering (IPO) on the Tel Aviv Stock Exchange (TASE) and raised $50 million at a pre-money valuation of ~$200 million. The IPO was led by Barak Capital Underwriters. The company has developed Synchronous Ul
- Dove, Conservation International Announce Million Dollar Forest Restoration Project to Fight Climate Changehttps://practicaldermatology.com/news/dove-conservation-international-announce-million-dollar-forest-restoration-project-to-fight-climate-change/2460822/Dove is launching the Dove Forest Restoration Project, one of the biggest protection and restoration efforts from any beauty brand to-date. The project is designed to protect and restore forests, protect the habitats of endangered species, and improve the livelihoods of 16,000 peo
- AstraZeneca's Anifrolumab Shows Benefit for Skin, Joint Symptoms of Lupushttps://practicaldermatology.com/news/astrazenecas-anifrolumab-shows-benefit-for-skin-joint-symptoms-of-lupus/2460819/Anifrolumab is consistently associated with improvements in both skin rash and arthritis across three different disease measures in patients with moderate to severe systemic lupus erythematosus (SLE), results of a new post-hoc analysis of pooled data from the TULIP phase 3 clinical trials show. T